AstraZeneca PLC (NASDAQ: AZN) and Daiichi Sankyo Company, Limited (Tokyo Stock Exchange: 4568) have secured European Commission approval for Enhertu (trastuzumab deruxtecan) as adjuvant treatment for adults with resected HER2-positive breast cancer who have residual invasive disease following neoadjuvant taxane-based and HER2-targeted treatment. Announced on October 26, 2026, the decision follows Phase 3 DESTINY-Breast05 results demonstrating a 53% reduction in the hazard of invasive disease recurrence or death compared with trastuzumab emtansine, commonly known as T-DM1.
The approval introduces Enhertu into the European Union’s curative-intent early breast cancer treatment setting, expanding its use beyond previously authorised indications in advanced and metastatic disease. It follows a positive recommendation issued by the European Medicines Agency’s Committee for Medicinal Products for Human Use on September 17, 2026.
The clinical evidence is particularly consequential because patients with residual invasive HER2-positive breast cancer after preoperative treatment face an increased risk of recurrence despite undergoing surgery and receiving additional systemic therapy. DESTINY-Breast05 directly compared Enhertu with an established active adjuvant treatment rather than placebo, providing evidence relevant to an existing clinical decision.
However, the improvement in disease-free survival must be weighed against the medicine’s known risk of interstitial lung disease and pneumonitis, including potentially fatal cases. Overall survival findings also remain immature, meaning that the demonstrated reduction in recurrence risk cannot yet be described as a confirmed improvement in long-term survival.
What exactly has the European Commission approved for Enhertu in early breast cancer?
The newly authorised indication covers Enhertu as monotherapy for adult patients with resected HER2-positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2-targeted treatment.
HER2-positive status is defined through immunohistochemistry demonstrating strong HER2 protein expression, classified as IHC 3+, or a positive in-situ hybridisation result indicating HER2 gene amplification.
This molecular requirement is important because the indication does not extend to all patients with early breast cancer. It specifically concerns tumors meeting the authorised HER2-positive criteria, rather than HER2-low or HER2-ultralow disease categories used in some advanced breast cancer treatment settings.
The treatment is administered after surgery, when residual invasive cancer has been identified following preoperative systemic therapy. This distinguishes adjuvant treatment from neoadjuvant therapy, which is given before surgery with the objective of reducing the primary tumor burden and addressing systemic disease.
The new approval follows the completed European regulatory process, not merely acceptance of an application or a positive committee opinion. The September recommendation by the Committee for Medicinal Products for Human Use was followed by the European Commission’s final authorisation announced on October 26.
The European approval is also not Enhertu’s first authorisation for this indication worldwide. The United States Food and Drug Administration approved the medicine for post-neoadjuvant residual HER2-positive early breast cancer on May 15, 2026, alongside a separate neoadjuvant indication based on another Phase 3 programme.
For European oncology practice, the October decision establishes a new authorised systemic treatment option after surgery in the specified patient population. Actual access will still depend on national and regional reimbursement arrangements, local clinical guidance and healthcare delivery requirements.
How did DESTINY-Breast05 demonstrate a 53% reduction in invasive disease recurrence or death?
DESTINY-Breast05 was a global, randomised, open-label Phase 3 trial involving 1,635 patients with HER2-positive early breast cancer and residual invasive disease following neoadjuvant therapy. Participants were considered at high risk of recurrence based on disease characteristics before treatment or persistent lymph-node involvement following preoperative therapy.
Patients were randomly assigned to receive Enhertu at 5.4 milligrams per kilogram or trastuzumab emtansine, with 818 participants allocated to Enhertu and 817 to the comparator group.
Both medicines were administered intravenously every three weeks for up to 14 cycles, or until recurrence or unacceptable toxicity. This provided a direct comparison between two HER2-targeted antibody-drug conjugates within a treatment setting where the objective is to reduce the risk of cancer returning after potentially curative therapy.
The primary endpoint was invasive disease-free survival, defined through the occurrence of specified invasive breast cancer recurrence events or death. This endpoint is clinically meaningful because it addresses whether patients remain free from invasive disease after completing their initial treatment sequence.
At the July 2, 2025 data cutoff, the median follow-up was approximately 30 months.
Invasive disease recurrence or death had occurred in 51 of 818 patients receiving Enhertu, representing approximately 6.2% of the group, compared with 102 of 817 patients receiving trastuzumab emtansine, representing approximately 12.5%.
The resulting hazard ratio was 0.47, with a 95% confidence interval ranging from 0.34 to 0.66 and a p-value below 0.0001.
This corresponds to a statistically significant 53% lower hazard of invasive disease recurrence or death among patients receiving Enhertu compared with the active control.
At three years, estimated invasive disease-free survival reached 92.4% with Enhertu and 83.7% with trastuzumab emtansine.
The 8.7-percentage-point absolute difference provides an important complement to the relative hazard reduction. It indicates that a greater proportion of patients receiving Enhertu remained alive without an invasive disease event at the three-year assessment.
The trial therefore provides direct randomised evidence of superior invasive disease-free survival compared with the previous established treatment option in the studied high-risk population.
Why is residual invasive disease after neoadjuvant treatment an important predictor of recurrence risk?
HER2-positive breast cancer is characterised by increased HER2 receptor activity, which can promote malignant cell growth and survival. HER2-targeted therapies have substantially improved outcomes, particularly when combined with chemotherapy in early-stage disease.
However, treatment response varies between patients.
Some individuals achieve a pathological complete response following neoadjuvant therapy, meaning that no residual invasive cancer is identified in the relevant breast and lymph-node specimens under the applicable pathological definition.
Others continue to have residual invasive disease despite receiving HER2-targeted treatment and chemotherapy before surgery.
The presence of residual disease can indicate a higher risk of subsequent recurrence, particularly when cancer remains in the axillary lymph nodes or when the original disease was locally advanced.
This creates a rationale for changing the postoperative treatment strategy rather than automatically continuing the same systemic medicines used before surgery.
The concept is often described as response-adapted treatment, where information obtained from the surgical specimen influences subsequent therapy.
For patients with residual invasive HER2-positive cancer, the objective of additional treatment is to eliminate or suppress microscopic malignant cells that may remain after surgery.
These cells may not be detectable on routine imaging but could contribute to future local recurrence or distant metastatic disease.
A medicine capable of reducing recurrence in this setting could provide substantial clinical value because the treatment is delivered while the patient remains free of known distant metastases.
However, early-stage treatment also involves a demanding benefit-risk calculation. Many patients may remain disease-free with existing therapy, and exposing them to a more intensive medicine creates the possibility of serious adverse effects without an individually predictable benefit.
The strength of the DESTINY-Breast05 results lies in demonstrating that additional treatment efficacy can be achieved against an active comparator in a population already receiving modern HER2-directed care.
How does Enhertu differ from trastuzumab emtansine, the established adjuvant comparator?
Trastuzumab emtansine, marketed as KADCYLA, became an established adjuvant option following the Phase 3 KATHERINE trial.
That study demonstrated that T-DM1 significantly reduced invasive recurrence or death compared with trastuzumab alone in patients with residual invasive HER2-positive breast cancer after neoadjuvant treatment.
The KATHERINE findings helped establish a response-adapted approach to postoperative treatment, making T-DM1 an important reference standard for subsequent clinical development.
Enhertu and trastuzumab emtansine both target HER2, but they differ in the cytotoxic payloads, linker chemistry and pharmacological characteristics of their antibody-drug conjugate designs.
Enhertu combines a HER2-directed antibody with a cleavable linker and a topoisomerase I inhibitor payload derived from exatecan. The medicine is designed to deliver cytotoxic activity following target binding and cellular uptake.
Trastuzumab emtansine uses a HER2-directed antibody linked to the microtubule inhibitor DM1 through a different linker system.
These design differences create distinct mechanisms of cytotoxic action despite both treatments recognising the same receptor.
Enhertu has also been developed to produce a potential bystander effect, in which released payload may affect nearby cancer cells beyond those with the highest HER2 expression.
This characteristic may be relevant in tumors with heterogeneous HER2 expression, although the clinical contribution of the bystander effect cannot be isolated from the overall efficacy findings in DESTINY-Breast05.
The trial establishes that Enhertu improved invasive disease-free survival compared with T-DM1, not that a single design characteristic independently accounts for the treatment advantage.
The direct comparison is nevertheless important because it provides stronger evidence than would be available from comparing response or recurrence rates reported in unrelated studies.
What do the additional disease-free survival and distant recurrence findings show?
Beyond the primary endpoint, DESTINY-Breast05 evaluated broader disease-free survival, which included additional cancer events not captured within the primary invasive disease-free survival definition.
In the published analysis, disease-free survival events occurred in 52 patients receiving Enhertu and 103 receiving trastuzumab emtansine.
The hazard ratio was 0.47, with a 95% confidence interval from 0.34 to 0.66 and a p-value below 0.0001.
Estimated three-year disease-free survival was 92.3% in the Enhertu group and 83.5% in the comparator group.
The consistency between invasive disease-free survival and the broader disease-free survival endpoint strengthens the interpretation that the observed benefit was not confined to a narrowly defined event category.
The study also reported favourable findings for the distant recurrence-free interval, an endpoint relevant to the development of cancer outside the original breast region.
At three years, estimated distant recurrence-free rates were 93.9% with Enhertu and 86.1% with T-DM1. The reported hazard ratio was 0.49, with a 95% confidence interval from 0.34 to 0.71.
Distant recurrence is particularly important because the development of metastatic breast cancer can substantially change treatment objectives and long-term prognosis.
The results suggest that the improvement in disease control includes a meaningful reduction in distant recurrence events during the observed period.
The study also evaluated brain metastasis-free outcomes, with a hazard ratio of 0.64. However, the corresponding 95% confidence interval ranged from 0.35 to 1.17, meaning that the result did not establish a statistically significant difference.
Consequently, the data do not justify a definitive claim that Enhertu prevents brain metastases in this treatment setting.
The broader evidence package supports an improvement in recurrence-related outcomes, while the clinical interpretation of individual secondary endpoints must remain consistent with their statistical maturity.
Has Enhertu demonstrated an overall survival advantage in early HER2-positive breast cancer?
The available DESTINY-Breast05 analysis has not established a statistically significant improvement in overall survival.
At the reported cutoff, 18 deaths had occurred in the Enhertu group and 29 in the trastuzumab emtansine group.
The estimated overall survival hazard ratio was approximately 0.61, with a 95% confidence interval from 0.34 to 1.10.
Although the numerical result favoured Enhertu, the confidence interval included the possibility of no survival difference.
The overall survival data were also highly immature, with only a small proportion of the expected information available.
This limitation is understandable in an early breast cancer trial where many participants remain alive and free of disease several years after treatment.
Nevertheless, it creates an important boundary around the interpretation of the approval.
The 53% reduction refers to the hazard of invasive disease recurrence or death under the primary composite endpoint. It does not establish that Enhertu reduces the hazard of death by 53%, nor does it demonstrate an equivalent improvement in long-term survival.
Further follow-up will be necessary to determine whether the reduction in invasive recurrence translates into a statistically significant overall survival benefit.
The timing and effectiveness of subsequent treatments may also influence survival outcomes among patients whose cancer eventually returns.
For oncology teams, the established benefit in invasive disease-free survival provides a strong basis for considering the authorised treatment, but it must be weighed against the safety risks of adding a potent antibody-drug conjugate during curative-intent care.
Why does interstitial lung disease remain a central safety concern for Enhertu?
Enhertu’s most consequential established safety risk is interstitial lung disease and pneumonitis, which can cause serious lung injury and may be fatal.
This concern is especially important in early breast cancer because patients are receiving treatment with the objective of remaining free from future disease, rather than managing known metastatic cancer.
In DESTINY-Breast05, adjudicated drug-related interstitial lung disease occurred in 9.6% of patients receiving Enhertu, compared with 1.6% receiving trastuzumab emtansine.
Two patients in the Enhertu group died from interstitial lung disease.
These trial-specific results demonstrate a meaningful difference in pulmonary toxicity between the treatment arms. They must be considered directly alongside the improvement in recurrence-related outcomes.
The company also reported safety findings from a broader pooled population of 4,146 patients receiving Enhertu at 5.4 milligrams per kilogram across multiple cancer studies.
In that pooled analysis, Grade 3 or 4 adverse reactions included neutropenia in 18.7%, anemia in 8.2%, fatigue in 7.4%, leukopenia in 6.6% and thrombocytopenia in 5.4%.
Grade 5 adverse reactions occurred in 0.9% of patients in the pooled dataset, including fatal interstitial lung disease or pneumonitis in 0.8%.
These broader safety percentages should not be mistaken for adverse-event rates observed specifically in DESTINY-Breast05. The pooled population includes different cancers, treatment histories and clinical settings.
Within DESTINY-Breast05, the peer-reviewed findings also identified nausea, constipation, reduced neutrophil counts and vomiting among common adverse events associated with Enhertu.
The distinct gastrointestinal and hematological toxicity profiles of Enhertu and T-DM1 reinforce the importance of evaluating both efficacy and tolerability rather than relying on the primary endpoint alone.
European prescribing information includes requirements for monitoring patients for potential interstitial lung disease and taking appropriate action when suspected or confirmed.
The possibility of serious pulmonary toxicity may affect treatment eligibility, monitoring and decisions about continuing therapy.
For hospitals and oncology services, implementation therefore involves more than changing a drug order. Teams must be equipped to recognise respiratory symptoms, investigate suspected adverse reactions and coordinate appropriate management.
The benefit-risk assessment is particularly consequential in patients with underlying pulmonary disease or other factors that may complicate treatment.
The Phase 3 results establish a significant improvement in disease control, but the pulmonary safety burden remains a material part of the clinical decision.
How could the new indication affect breast cancer treatment pathways across Europe?
The European approval creates an additional authorised option for patients whose surgical pathology identifies residual invasive HER2-positive breast cancer after qualifying neoadjuvant therapy.
This may influence multidisciplinary treatment decisions involving medical oncologists, breast surgeons, pathologists and specialist nurses.
The timing of HER2 testing and confirmation of residual disease will remain important because eligibility depends on both molecular status and the clinical treatment sequence.
HER2 assessment is already integral to breast cancer diagnosis and treatment planning, but the expanded indication increases the importance of maintaining accurate pathological records across neoadjuvant treatment, surgery and postoperative care.
Oncology teams will also need to evaluate treatment tolerance, previous therapy and the feasibility of completing the intended adjuvant regimen.
DESTINY-Breast05 used up to 14 cycles of treatment administered every three weeks. This represents a substantial period of systemic therapy, requiring repeated infusion appointments and ongoing monitoring.
The practicality of delivering this regimen may differ among hospitals depending on infusion capacity, pharmacy resources and access to specialist toxicity management.
Reimbursement represents another important requirement.
European Commission marketing authorisation permits use within the approved regulatory framework, but it does not automatically establish uniform reimbursement or immediate availability across every European Union member state.
National and regional authorities may conduct health technology assessments, negotiate pricing or establish eligibility requirements before broad funded access becomes available.
The availability of T-DM1 as an established adjuvant treatment also creates a meaningful comparator for economic evaluation.
Health systems will need to assess the incremental clinical benefit of Enhertu relative to acquisition costs, infusion requirements, monitoring and adverse-event management.
The observed absolute difference in three-year invasive disease-free survival will be a relevant consideration, alongside longer-term outcomes and the additional pulmonary toxicity risk.
Why does the approval trigger a $75 million payment from AstraZeneca to Daiichi Sankyo?
The European Commission decision also carries a direct contractual consequence for the companies’ oncology collaboration.
Under their March 2019 agreement governing Enhertu, the new European adjuvant approval triggers a $75 million milestone payment from AstraZeneca to Daiichi Sankyo.
Unlike potential future regulatory or commercial milestones, this amount has become payable following the specified approval event.
The transaction illustrates how expanding an established medicine into additional indications can generate contractual payments independently of immediate product sales.
Daiichi Sankyo records sales of Enhertu in most European Union territories, making the Japanese pharmaceutical developer the principal sales-recognising party for much of the region under the collaboration structure.
The financial benefits to AstraZeneca arise through its contractual participation and commercial arrangements, which differ from recognising the same European product sales directly.
The agreement has supported the global development of Enhertu across multiple tumor types and treatment settings.
The latest authorisation extends the franchise into a curative-intent population where treatment objectives differ from those in advanced or metastatic disease.
Commercial performance will depend on the number of eligible patients, reimbursement coverage, physician adoption and the extent to which the benefit-risk profile supports use in routine practice.
The $75 million milestone is a confirmed transaction-related consequence of the approval, but it should not be interpreted as the expected value of the European market or as a forecast of incremental annual revenue.
What does Enhertu’s financial performance indicate about the importance of earlier breast cancer indications?
Enhertu has become an important growth product for Daiichi Sankyo’s global oncology business.
For the first quarter of fiscal year 2026, ending June 30, Daiichi Sankyo reported revenue of approximately ¥574.7 billion, representing year-on-year growth of 21.1%.
Enhertu-related revenue, including milestone payments, reached approximately ¥239.8 billion, increasing 48.9% from the corresponding period of the previous year.
The distinction between product sales and total Enhertu-related revenue is important because the latter includes certain collaboration and milestone payments.
The new European adjuvant indication creates an additional potential growth opportunity within an already commercialised product franchise.
Unlike a new medicine requiring the establishment of an entirely separate commercial infrastructure, Enhertu benefits from existing oncology distribution, medical education and specialist treatment networks.
However, introduction into early breast cancer may require additional training and clinical pathways because the acceptable balance between treatment efficacy and toxicity differs from that in metastatic disease.
For Daiichi Sankyo, the commercial opportunity will depend on the authorised population, national reimbursement decisions and treatment uptake across European markets.
For AstraZeneca, the approval adds another indication to a broad oncology collaboration while reinforcing its strategic position in antibody-drug conjugate development.
The companies have not provided a specific forecast for incremental European sales attributable exclusively to the October 2026 approval.
AstraZeneca’s United States-listed shares closed at approximately $172.06 on October 26, rising 0.3% from the previous session.
Daiichi Sankyo shares closed at ¥2,825 in Tokyo on the same date, advancing approximately 0.3%.
Neither price movement establishes a direct market reaction to the European Commission decision because both businesses are influenced by wider pharmaceutical portfolios, earnings expectations and other developments.
The approval provides a confirmed regulatory and contractual milestone, while the longer-term financial effect remains dependent on commercial implementation.
How does the EU decision strengthen Enhertu’s broader early breast cancer development strategy?
Enhertu’s European adjuvant approval forms part of a broader effort to move antibody-drug conjugates into earlier cancer treatment settings.
The medicine had already demonstrated substantial activity in metastatic HER2-positive breast cancer, helping establish its role in treatment pathways where patients have advanced disease.
DESTINY-Breast05 demonstrates that the same therapeutic platform can also reduce recurrence-related outcomes after surgery in a selected high-risk early breast cancer population.
However, efficacy in metastatic disease and prevention of recurrence after curative-intent treatment involve different clinical objectives and patient populations.
The broader development programme also includes DESTINY-Breast11, which investigated Enhertu-based treatment before surgery in HER2-positive early breast cancer.
The United States approved a separate Enhertu-containing neoadjuvant regimen in May 2026 based on that programme, alongside the adjuvant authorisation supported by DESTINY-Breast05.
These are distinct indications with different treatment sequences.
The neoadjuvant programme evaluates treatment before surgery, while DESTINY-Breast05 supports treatment after surgery when residual invasive disease is present.
They should not be combined into a single unrestricted early breast cancer indication or treated as evidence that Enhertu can replace every established HER2-targeted regimen.
The overall strategy reflects increasing interest in using more active systemic treatments to reduce recurrence risk before metastatic disease develops.
Its success will depend on identifying patients whose expected benefit justifies more intensive therapy while avoiding unnecessary exposure among individuals who may already have favourable outcomes with existing treatments.
What will determine Enhertu’s long-term position in HER2-positive early breast cancer?
The DESTINY-Breast05 results establish that Enhertu significantly improves invasive disease-free survival compared with trastuzumab emtansine in patients with high-risk residual invasive HER2-positive breast cancer following neoadjuvant treatment.
The magnitude of the benefit is supported by both the 53% relative hazard reduction and the 8.7-percentage-point absolute improvement in three-year invasive disease-free survival.
The evidence is particularly relevant because the trial used an established active comparator rather than placebo.
However, two important questions remain.
The first concerns whether the reduction in recurrence-related events ultimately translates into a statistically significant overall survival advantage with longer follow-up.
The second concerns how the risk of serious interstitial lung disease, including fatal cases, should influence treatment selection and monitoring within a curative-intent population.
The European approval resolves the regulatory question of whether Enhertu can be marketed for the specified adjuvant indication. It does not eliminate the need for ongoing safety monitoring or determine which patients will experience the greatest individual benefit.
For AstraZeneca and Daiichi Sankyo, the decision expands an established antibody-drug conjugate into an earlier treatment setting with meaningful clinical and commercial potential.
The next stage will be determined by national market access, real-world treatment experience and longer-term survival evidence.
Enhertu has demonstrated a substantial ability to reduce invasive breast cancer recurrence compared with the previous standard adjuvant treatment. Its long-term position will depend on preserving that benefit while managing the pulmonary toxicity that remains central to the medicine’s clinical profile.
